Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Hans C. Lee
Noopur S. Raje
Ola Landgren
Vijay V. Upreti
Jin Wang
Ariel A. Avilion
Xuguang Hu
Erik Rasmussen
Gataree Ngarmchamnanrith
Hisaki Fujii
Andrew Spencer
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Lymphoma/Myeloma
[2] Harvard Medical School,Center for Multiple Myeloma, Massachusetts General Hospital
[3] Memorial Sloan Kettering Cancer Center,Myeloma Service, Department of Medicine
[4] Amgen Inc.,Clinical Pharmacology Modeling & Simulation
[5] Amgen Inc.,Bioanalytical Sciences
[6] Amgen Inc.,Clinical Biomarkers & Diagnostics
[7] Amgen Inc.,Global Biostatistical Science
[8] Amgen Inc.,Clinical Development
[9] Amgen Inc.,Translational Medicine
[10] Monash University,Malignant Haematology & Stem Cell Transplantation Service, The Alfred Hospital
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：255 / 258
页数：3
相关论文
共 50 条
  • [41] Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma
    Stefanie Palfi
    Lauren C. Peres
    Himara Koelmeyer
    Melissa Alsina
    Rachid C. Baz
    Brandon J. Blue
    Salvatore Corallo
    Gabriel De Avila
    Ciara Freeman
    Rebecca Gonzalez
    Ariel Grajales-Cruz
    Kristy Harvey
    Hien D. Liu
    Taiga Nishihori
    Guilherme H. Oliveira
    Laura B. Oswald
    Omar Castaneda Puglianini
    Sruthi Selvakumar
    Alexis Behne Sharma
    Elicia Wang
    Kenneth H. Shain
    Michael Jain
    Frederick L. Locke
    Mohammed Alomar
    Doris K. Hansen
    Dae Hyun Lee
    Blood Cancer Journal, 15 (1)
  • [42] Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
    Raje, Noopur
    Berdeja, Jesus
    Lin, Yi
    Siegel, David
    Jagannath, Sundar
    Madduri, Deepu
    Liedtke, Michaela
    Rosenblatt, Jacalyn
    Maus, Marcela V.
    Turka, Ashley
    Lam, Lyh-Ping
    Morgan, Richard A.
    Friedman, Kevin
    Massaro, Monica
    Wang, Julie
    Russotti, Greg
    Yang, Zhihong
    Campbell, Timothy
    Hege, Kristen
    Petrocca, Fabio
    Quigley, M. Travis
    Munshi, Nikhil
    Kochenderfer, James N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (18): : 1726 - 1737
  • [43] Outcomes of Anti-BCMA CAR T Cell Therapy for Relapsed/refractory Multiple Myeloma: A Meta-Analysis
    Gagelmann, Nico
    Ayuk, Francis
    Atanackovic, Djordje
    Kroeger, Nicolaus
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 130 - 130
  • [44] A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma
    Cornell, Robert F.
    Bishop, Michael R.
    Kumar, Shaji
    Giralt, Sergio A.
    Nooka, Ajay K.
    Larson, Sarah M.
    Locke, Frederick L.
    Raje, Noopur S.
    Lei, Lei
    Dong, Jinghui
    Gall, John B. Le
    Rossi, John M.
    Orlowski, Robert Z.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (06): : 3285 - 3293
  • [45] Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
    Qu, Xiaoyan
    An, Gang
    Sui, Weiwei
    Wang, Tingyu
    Zhang, Xian
    Yang, Junfang
    Zhang, Yan
    Zhang, Lu
    Zhu, Judy
    Huang, Jiaqi
    Li, Jing
    Zheng, Shirley
    Zhu, Kevin
    Lan, Liping
    Chen, Shiyi
    Humphries, Michael
    Yao, Yihong
    Zhou, Daobin
    Lu, Peihua
    Qiu, Lugui
    Li, Jianyong
    BLOOD, 2021, 138 : 1830 - +
  • [46] First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
    Vij, Ravi
    Nath, Rajneesh
    Afar, Daniel E. H.
    Mateos, Maria Victoria
    Berdeja, Jesus G.
    Raab, Marc S.
    Guenther, Andreas
    Martinez-Lopez, Joaquin
    Jakubowiak, Andrzej J.
    Leleu, Xavier
    Weisel, Katja
    Wong, Shekman
    Gulbranson, Scott
    Sheridan, James P.
    Reddy, Anita
    Paiva, Bruno
    Singhal, Anil
    San-Miguel, Jesus F.
    Moreau, Philippe
    CLINICAL CANCER RESEARCH, 2020, 26 (10) : 2308 - 2317
  • [47] Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
    Jarrod Longcor
    Natalie Callander
    Kate Oliver
    Asher Chanan-Khan
    Sikander Ailawadhi
    Blood Cancer Journal, 12
  • [48] Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
    Longcor, Jarrod
    Callander, Natalie
    Oliver, Kate
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    BLOOD CANCER JOURNAL, 2022, 12 (09)
  • [49] Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma
    Popat, Rakesh
    Cheok, Kathleen
    Sridhar, Amrutha
    Feely, Conor
    Mactier, Catriona
    Mcmillan, Annabel
    Wechalekar, Ashutosh D.
    Rabin, Neil
    Sive, Jonathan
    Kyriakou, Charalampia
    Xu, Ke
    Papanikolaou, Xenofon
    Mahmood, Shameem
    Yong, Kwee
    Lee, Lydia Sarah Hui
    BLOOD, 2023, 142
  • [50] HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma
    Pahl, Andreas
    Ko, Jonathan
    Breunig, Christian
    Figueroa, Vianiuhini
    Lehners, Nicola
    Baumann, Anja
    Palfi, Aniko
    Mueller, Christoph
    Lutz, Christian
    Hechler, Torsten
    Kulke, Michael
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Raab, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345